Small Molecules

11 Apr 2021 Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
11 Apr 2021 Investigational Combination of Aliqopa® (copanlisib) and rituximab Significantly Increases Progression-Free Survival in Patients with Relapsed Indolent non-Hodgkin's Lymphoma
09 Apr 2021 ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting
09 Apr 2021 Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer
09 Apr 2021 Nimbus Therapeutics Presents In Vivo Data Showing Single-Agent and Combination Activity of HPK1 Inhibitor
08 Apr 2021 Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
07 Apr 2021 Phase 1/2 Trial Initiated for Daiichi Sankyo’s Menin Inhibitor DS-1594 in Patients with Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
07 Apr 2021 Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases
07 Apr 2021 Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
07 Apr 2021 Artios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
07 Apr 2021 Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
06 Apr 2021 Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
06 Apr 2021 Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
02 Apr 2021 Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial
02 Apr 2021 United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
02 Apr 2021 SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
02 Apr 2021 FDA Grants Breakthrough Therapy Designation for Taiho Oncology’s Futibatinib for Treatment of Advanced Cholangiocarcinoma
31 Mar 2021 European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
31 Mar 2021 Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
31 Mar 2021 Amgen to Acquire Rodeo Therapeutics Corporation
30 Mar 2021 Amarin Receives European Commission (EC) Approval for VAZKEPA to Reduce Cardiovascular Risk
30 Mar 2021 Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate
30 Mar 2021 Karyopharm Receives Conditional Marketing Authorization from the European Commission for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
30 Mar 2021 Astellas' XOSPATA® (gilteritinib) Meets Overall Survival Endpoint in COMMODORE Trial of Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
30 Mar 2021 Daiichi Sankyo Initiates Phase 1 Trial for Nafamostat Inhalation Formulation (DS-2319) in Japan

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up